Cargando…
Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia
Histological distinction between epithelioid mesothelioma (EM) and reactive mesothelial hyperplasia (RMH) can be challenging. The aim of this study was to assess the diagnostic utility of Survivin, Ki-67, and loss of BRCA1-associated protein 1 (BAP1) expressions in distinguishing EM from RMH using i...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796295/ https://www.ncbi.nlm.nih.gov/pubmed/29467873 http://dx.doi.org/10.3892/ol.2018.7765 |
_version_ | 1783297478559268864 |
---|---|
author | Kushitani, Kei Amatya, Vishwa Jeet Mawas, Amany Sayed Suzuki, Rui Miyata, Yoshihiro Okada, Morihito Inai, Kouki Kishimoto, Takumi Takeshima, Yukio |
author_facet | Kushitani, Kei Amatya, Vishwa Jeet Mawas, Amany Sayed Suzuki, Rui Miyata, Yoshihiro Okada, Morihito Inai, Kouki Kishimoto, Takumi Takeshima, Yukio |
author_sort | Kushitani, Kei |
collection | PubMed |
description | Histological distinction between epithelioid mesothelioma (EM) and reactive mesothelial hyperplasia (RMH) can be challenging. The aim of this study was to assess the diagnostic utility of Survivin, Ki-67, and loss of BRCA1-associated protein 1 (BAP1) expressions in distinguishing EM from RMH using immunohistochemistry. Formalin-fixed, paraffin-embedded specimens from 78 cases of EM and 80 cases of RMH were immunohistochemically examined for Survivin, BAP1, and Ki-67. In addition, receiver operating characteristic curve analyses were performed to establish the cut-off values for Survivin and Ki-67 labelling indices. Survivin (cut-off value: 5%) had 67.7% sensitivity and 100% specificity, while Ki-67 (cut-off value: 10%) had 85.1% sensitivity and 87.5% specificity, and BAP1 had 66.2% sensitivity and 100% specificity for the differentiation of EM from RMH. Among the combinations of two markers, the combination of Survivin and BAP1 (Survivin-positive and/or BAP1-loss finding) had the highest diagnostic accuracy (sensitivity: 89.8%; specificity: 100%; accuracy: 95.3%). We recommend using the combination of Survivin and BAP1 to distinguish EM from RMH. |
format | Online Article Text |
id | pubmed-5796295 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-57962952018-02-21 Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia Kushitani, Kei Amatya, Vishwa Jeet Mawas, Amany Sayed Suzuki, Rui Miyata, Yoshihiro Okada, Morihito Inai, Kouki Kishimoto, Takumi Takeshima, Yukio Oncol Lett Articles Histological distinction between epithelioid mesothelioma (EM) and reactive mesothelial hyperplasia (RMH) can be challenging. The aim of this study was to assess the diagnostic utility of Survivin, Ki-67, and loss of BRCA1-associated protein 1 (BAP1) expressions in distinguishing EM from RMH using immunohistochemistry. Formalin-fixed, paraffin-embedded specimens from 78 cases of EM and 80 cases of RMH were immunohistochemically examined for Survivin, BAP1, and Ki-67. In addition, receiver operating characteristic curve analyses were performed to establish the cut-off values for Survivin and Ki-67 labelling indices. Survivin (cut-off value: 5%) had 67.7% sensitivity and 100% specificity, while Ki-67 (cut-off value: 10%) had 85.1% sensitivity and 87.5% specificity, and BAP1 had 66.2% sensitivity and 100% specificity for the differentiation of EM from RMH. Among the combinations of two markers, the combination of Survivin and BAP1 (Survivin-positive and/or BAP1-loss finding) had the highest diagnostic accuracy (sensitivity: 89.8%; specificity: 100%; accuracy: 95.3%). We recommend using the combination of Survivin and BAP1 to distinguish EM from RMH. D.A. Spandidos 2018-03 2018-01-10 /pmc/articles/PMC5796295/ /pubmed/29467873 http://dx.doi.org/10.3892/ol.2018.7765 Text en Copyright: © Kushitani et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Kushitani, Kei Amatya, Vishwa Jeet Mawas, Amany Sayed Suzuki, Rui Miyata, Yoshihiro Okada, Morihito Inai, Kouki Kishimoto, Takumi Takeshima, Yukio Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia |
title | Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia |
title_full | Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia |
title_fullStr | Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia |
title_full_unstemmed | Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia |
title_short | Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia |
title_sort | utility of survivin, bap1, and ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796295/ https://www.ncbi.nlm.nih.gov/pubmed/29467873 http://dx.doi.org/10.3892/ol.2018.7765 |
work_keys_str_mv | AT kushitanikei utilityofsurvivinbap1andki67immunohistochemistryindistinguishingepithelioidmesotheliomafromreactivemesothelialhyperplasia AT amatyavishwajeet utilityofsurvivinbap1andki67immunohistochemistryindistinguishingepithelioidmesotheliomafromreactivemesothelialhyperplasia AT mawasamanysayed utilityofsurvivinbap1andki67immunohistochemistryindistinguishingepithelioidmesotheliomafromreactivemesothelialhyperplasia AT suzukirui utilityofsurvivinbap1andki67immunohistochemistryindistinguishingepithelioidmesotheliomafromreactivemesothelialhyperplasia AT miyatayoshihiro utilityofsurvivinbap1andki67immunohistochemistryindistinguishingepithelioidmesotheliomafromreactivemesothelialhyperplasia AT okadamorihito utilityofsurvivinbap1andki67immunohistochemistryindistinguishingepithelioidmesotheliomafromreactivemesothelialhyperplasia AT inaikouki utilityofsurvivinbap1andki67immunohistochemistryindistinguishingepithelioidmesotheliomafromreactivemesothelialhyperplasia AT kishimototakumi utilityofsurvivinbap1andki67immunohistochemistryindistinguishingepithelioidmesotheliomafromreactivemesothelialhyperplasia AT takeshimayukio utilityofsurvivinbap1andki67immunohistochemistryindistinguishingepithelioidmesotheliomafromreactivemesothelialhyperplasia |